Minapharm Secures Strategic Investment to Expand Biotechnology footprint
Table of Contents
Triquera B.V., the majority shareholder of Egyptian biopharmaceutical leader Minapharm, has finalized a minority investment deal with Admaius Capital Partners. This important transaction is poised to accelerate the regional and global expansion of Minapharm’s biotechnology capabilities.
admaius, a private equity firm with a focus on Africa, is partnering with Triquera to bolster the growth of Minapharm. The company operates one of the largest biological drug substance and product facilities in the Middle East and Africa. Minapharm is recognized for its complete end-to-end capabilities in manufacturing complex recombinant proteins, viral vectors, and advanced biologics, with operations spanning Cairo and Berlin.
This strategic alliance is anticipated to expedite the development and distribution of high-quality, affordable genetically engineered therapies, particularly for underserved markets across Africa and the Middle East. The partnership will also concentrate on broadening Minapharm’s licensing of proprietary technologies in areas such as monoclonal antibodies, cell and gene therapies, and vaccines. Many of these technologies have already been integrated into FDA-approved products.
Future plans stemming from this collaboration include exploring strategic acquisitions of global contract development and manufacturing organizations (CDMOs). This move aims to further solidify Minapharm’s position as a competitive entity within the global biotechnology industry.
Strategic Alignment and Regional Impact
Dr. Wafik Bardissi, Chairman and CEO of Minapharm, expressed enthusiasm for the partnership. “With Admaius, we gain not only capital but a strategic partner whose insight, alignment, and ambition match our own,” he stated. “Together, we are advancing regional self-sufficiency and expanding the global reach of our innovations.”
Marlon Chigwende, Managing Partner at Admaius capital Partners, characterized the deal as a “landmark transaction.” He added, “The founding families have built a unique asset on the African and European continents that combines scale, growth, and impact to fight cancer and other awful diseases.”
Ahmed Rady, Managing Director at Admaius, commended the Minapharm team’s scientific and operational expertise. “This partnership is about scaling a homegrown champion that combines cutting-edge global know-how with end-to-end manufacturing excellence,” Rady remarked.
Dr. Shaheer Bardissi, Co-CEO of Minapharm, highlighted the broader industry implications of the agreement. “This strategic collaboration with Admaius will accelerate and scale Minapharm’s vision of translating cutting-edge scientific innovation into affordable therapies, while advancing global scientific frontiers in immunotherapy and advanced therapy medicinal products,” he explained.
Advisory Teams
Zilla Capital served as the sole financial advisor to Triquera and its existing shareholders.
This content is for informational purposes only and does not constitute health, financial, or legal advice.
What are your thoughts on this strategic investment? Share your insights in the comments below, and subscribe to World Today News for more updates on global business and innovation.
